Arthritis drug effective in treating sickest COVID-19 patients | Imperial News | Imperial College London
Résultats préliminaires : le Tocilizumab est efficace dans les formes critiques de #COVID-19
The relative contribution of survival and reduced length of time needing organ support in ICU has not yet been analysed. The trial does not yet know the relative benefits of #tocilizumab compared to the other immune modulators. Further data are expected in the coming weeks and months.
Due to the clinical implications for patients, the researchers have released the findings before they have been peer-reviewed, but are working to analyse and publish the full results as soon as possible.
Professor Anthony Gordon, Chair in Anaesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust, said: “These early findings show that treatment with this immune modulating drug is effective for critically ill COVID-19 patients in intensive care units. When we have the results available from all participants, we hope our findings will offer clear guidance to clinicians for improving the outcomes of the sickest COVID-19 patients.”